Clinical Trials Logo

Clinical Trial Summary

Purpose of this study is to examine the effectiveness of an experimental psychotherapy (talk therapy) for the treatment of bipolar II depression. The name of this psychotherapy is Interpersonal and Social Rhythm Therapy for Bipolar II Depression (IPSRT-BPII). Subjects will be randomly assigned to receive either IPSRT-BPII or the medication Seroquel (quetiapine) to manage their symptoms of bipolar II depression. Subjects will receive the assigned therapy for up to 20 weeks.


Clinical Trial Description

The proposed pilot study is an experimental design intended to investigate the preliminary efficacy of Interpersonal Social Rhythm Therapy for Bipolar II Depression (IPSRT-BPII). A total of 56 eligible subjects with a diagnosis of bipolar II disorder will be randomly assigned to one of two treatment groups : Seroquel (n=28) or IPSRT-BPII (n=28). Following baseline assessment, all participants will undergo up to 20 weeks of their assigned treatment. Patients assigned to IPSRT-BPII who fail to respond (at least 50% reduction in HRSD-25 scores and YMRS ≤ 10) by week 12 will have Seroquel added to IPSRT-BPII. Subjects who achieve remission (defined as 3 consecutive weeks where both HRSD-25 and YMRS scores average ≤ 7) and have participated in the trial for a minimum of 12 weeks will be moved into a continuation phase where they will receive maintenance treatment (bi-monthly therapy sessions and/or pharmacotherapy) until week 20. Patients who do not achieve remission by Week 20 will be discontinued from treatment and referred for follow-up care. All subjects (remitters and non-remitters) will be assessed at 20 weeks. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00411463
Study type Interventional
Source University of Pittsburgh
Contact
Status Completed
Phase Phase 2/Phase 3
Start date December 2006
Completion date September 2010

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03641300 - Efficacy of Convulsive Therapies for Bipolar Depression N/A
Recruiting NCT05340686 - Braining- Aerobic Physical Activity as Add on Treatment in Bipolar Depression N/A
Completed NCT00761761 - Sensoril(Ashwaganhda)for Bipolar Disorder Phase 3
Active, not recruiting NCT04561622 - Emotional Proactive Processing in Bipolar Disorder
Completed NCT03334721 - Gabapentin for Bipolar & Cannabis Use Disorders Phase 2
Active, not recruiting NCT05658510 - Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III) Phase 3
Recruiting NCT06184581 - Lithium Versus Lamotrigine in Bipolar Disorder, Type II Phase 4
Active, not recruiting NCT03484494 - Low Field Magnetic Stimulation: Imaging Biomarkers in Geriatric Bipolar Depression N/A
Recruiting NCT05400785 - Efficacy of the Mobile Application for Prediction and Prevention of Mood Episode Recurrence Based on Machine Learning N/A
Completed NCT05340504 - Evaluating the Hypothesized Mechanism of Action of N-acetylcysteine for Bipolar Disorder Phase 2
Active, not recruiting NCT05249309 - Naturalistic Study of Ketamine in the Treatment of Depression
Recruiting NCT04211428 - A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Bipolar Disorder
Completed NCT03822416 - Treating Smokers With Mental Illness Phase 2
Completed NCT01588457 - Sequential Multiple Assignment Treatment for Bipolar Disorder Phase 4
Completed NCT03156504 - The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression. Phase 4
Recruiting NCT05004896 - Ketamine for Treatment-Resistant Bipolar Disorder Phase 2
Terminated NCT02491307 - Ginger.io Behavioral Health Study N/A
Recruiting NCT05427123 - Children's Bipolar Network Treatment Trial I
Not yet recruiting NCT05705063 - Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Bipolar Illness N/A
Recruiting NCT05065294 - Psilocybin Therapy for Depression in Bipolar II Disorder Phase 2